Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
Legend Biotech Corporation - American Depositary Shares (LEGN)
Company Research
Source: GlobeNewswire
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $555 million and $1.9 billion for the fourth quarter and full year 2025, respectivelySurpassed milestone of more than 10,000 patients treated with CARVYKTI®CARVYKTI now available across 294 sites worldwide; continued expansion in U.S. community settingsAdvanced early-stage cell therapy portfolio, including first-patient dosing of in vivo candidates and presentation of first-in-human results for LUCAR-G39D, an allogeneic CAR-T therapy Cash and cash equivalents, and time deposits of $949 million, as of December 31, 2025 SOMERSET, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported financial results for the fourth quarter and year ended December 31, 2025, and key corporate highlights. “CARVYKTI® continued to build on its leadership in multiple myeloma CAR-T in 2025, as we reached more than 10,000 patients tr
Show less
Read more
Impact Snapshot
Event Time:
LEGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEGN alerts
High impacting Legend Biotech Corporation - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
LEGN
News
- GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality GrowthPR Newswire
- GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality GrowthPR Newswire
- GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality GrowthPR Newswire
- Genscript Biotech Corp (GNNSF) Full Year 2025 Earnings Call Highlights: Record Revenue Growth ... [Yahoo! Finance]Yahoo! Finance
- Legend Biotech (LEGN) was upgraded by Truist Financial Corporation from "hold" to "strong-buy".MarketBeat
LEGN
Sec Filings
- 3/10/26 - Form 20-F
- 3/10/26 - Form 6-K
- 2/6/26 - Form 6-K
- LEGN's page on the SEC website